Biomet Inc., a global leader in the manufacture of musculoskeletal medical products, announced today the initial closing of the previously announced acquisition of the worldwide trauma business of DePuy Orthopaedics Inc.
As part of the initial closing, Biomet has acquired DePuy Trauma’s operations in the United States, the United Kingdom, Australia, New Zealand and Japan, as well as DePuy Trauma’s manufacturing operations in Le Locle, Switzerland. Biomet assumed responsibility for business operations at 12 a.m. Eastern time, June 16. Closings for the remaining countries will occur on a staggered basis and in general within the next 6 months and DePuy Orthopaedics affiliates will serve as Biomet’s interim distributor in these countries until these country operations are fully transitioned to Biomet.
”Today we take another step forward in our strategy to provide our surgeon and hospital customers with innovative products of the highest quality, and excellent service, on a global basis,” said Jeffrey R. Binder, President and CEO of Biomet. ”Trauma is one of the fastest-growing market segments in orthopaedics and at the core of orthopaedic care. I would like to extend a warm welcome to our new team members, and to surgeon and hospital customers around the world. All of us at Biomet look forward to working with you to fulfill our commitment to helping our customers improve the lives of their patients.”